Biotest AG / Key word(s): Profit Warning 28.04.2011 10:07 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad hoc ANNOUNCEMENT Announcement in accordance with Section 15 (1) of the German Securities Trading Act (WpHG) Dreieich, 28 April 2011. The Board of Management of Biotest AG has adjusted its 2011 earnings targets for the Continuing Operations of the Biotest Group but affirmed its sales goal. This is due to events at the subsidiary Biotest Pharmaceuticals Corporation (BPC), Boca Raton, USA, where problems with the automation and control software occurred upon the launch of the new production system. As a result, production of the polyspecific immunoglobulin BivigamTM will not begin until the second half of 2011, a few months later than planned. Meanwhile, the processing of the application for marketing authorisation for BivigamTM by the US Food and Drug Administration continues to progress quickly and smoothly. The results of inspections conducted so far have been positive and have generated no concerns. Marketing authorisation for BivigamTM will nevertheless be delayed, as data from consistency batches, which must be submitted before authorisation is granted, will not be available until later in the year. Due the extended idle time of the facility and the necessary repairs, Biotest will incur additional expenses initially estimated at EUR7 to EUR8 million, which will have a negative impact on earnings. Therefore, the previous goal of a 1% to 2% increase in EBIT over 2010 can no longer be met. Earnings performance is also subject to increased uncertainty in light of further changes in prices for plasma proteins in some parts of the world. Sales of the Biotest Group in Continuing Operations in the first quarter of 2011 totalled EUR106.5 million (2010: EUR102.8 million). In light of this development, Biotest has affirmed its sales goal for 2011 (1% to 2% growth over 2010 sales). Biotest Aktiengesellschaft The Board of Management Biotest AG Landsteinerstr. 5 63303 Dreieich, Germany www.biotest.de Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest is a provider of pharmaceutical and biotherapeutic drugs as well as reagents and systems for microbiology. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of application of immunology and haematology. In its Plasma Protein segment, Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. The products of the Microbiological Monitoring segment are primarily used in hygiene monitoring. Biotest has more than 1,900 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange. Securities' ID No., ISIN ordinary shares: 522720, DE0005227201 Securities' ID No., ISIN preference shares: 522723, DE0005227235 Listing: Prime Standard/Official traded Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart 28.04.2011 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Biotest AG LandsteinerstraÃe 5 63303 Dreieich Deutschland Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Indices: SDAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Biotest AG: Ad hoc ANNOUNCEMENT
| Source: EQS Group AG